Cross-species reactivity of seven monoclonal antibodies with equine lymphocytes by flow cytometry.

The research paper studies how seven monoclonal antibodies react with horse lymphocytes, discovering that three of them behave similarly to how they act with human cells, while the remaining four show different reactions or levels of expression.

Overview of the Study

• The researchers looked into the behaviour of seven different monoclonal antibodies (mAbs). These were monoclonal antibodies against human CD11a, CD18, CD21, CD23, CD29, DR, and mouse CD23. The medium of analysis was flow cytometry, a technique used to measure physical and chemical characteristics of cells or particles.
• The mAbs were applied to equine (horse) lymphocytes, which are white blood cells in the immune system. These were compared to their recognized behaviour on human lymphocytes.
• Interestingly, two different sets of results were found: one group of mAbs (against CD18, CD29, and DR) demonstrated a similar level of reaction with horse peripheral blood lymphocytes (PBL) as with human PBL, while the group formed by anti-CD11a, anti-CD21, and anti-CD23 mAbs either interacted with different molecules entirely or showed a distinct level of expression on horse PBL as compared to human PBL.

High Complexity in Immunochemistry

• Continuous double-staining experiments with anti-horse immunoglobulin antibodies demonstrated that anti-CD21 and anti-CD23 mAbs mostly bind to peripheral blood B lymphocytes. In simpler terms: a secondary round of staining using particular antibodies showed that two of the monoclonal antibodies mostly connected with a specific type of lymphocyte.
• All seven mAbs were also tested on lymph node and thymus cells to further evaluate their behaviour.
• Immunoprecipitation of membrane proteins was used to confirm the molecular targets of anti-CD11a, CD18, and CD29 mAbs.
• The findings from the study underscore the complexity and specificity involved in immunochemistry, and pave the way for further work in understanding how these specific monoclonal antibodies act at different levels of the equine immune system.